Lung Cancer

Factors Associated With Non-Small Cell Lung Cancer Stage at Presentation

By

Vicki Moore, PhD

Publish Date June 22, 2022

Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.

Health Disparities Effect Use of Precision Medicine Testing, Treatment in NSCLC

By

Jennifer Larson

Publish Date June 9, 2022

An analysis of published literature sought to measure the effects of social determinants of health on precision medicine for lung cancer in various racial and ethnic patient populations.

Follow-Up Often Delayed After High-Risk Findings on Lung Cancer Screening

Publish Date June 1, 2022

Patients with more severe findings less likely to have prolonged delays; current smokers had more delays than former smokers.

Less Biomarker Testing, Greater Risk of Death Seen in NSCLC Patients on Medicaid

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date May 26, 2022

Medicaid beneficiaries had a higher risk of death than commercially-insured patients, but the risk of death decreased if Medicaid beneficiaries underwent biomarker testing.

AYA Cancer Survivors Twice As Likely to Die From Second Cancer

By

Leah Lawrence

Publish Date May 23, 2022

The risk of dying from a subsequent primary cancer remained significantly elevated for 20 years or more for some patients.

Lung Cancer Clinical Trials

Clinical Trial: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer

Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)

Clinical Trial: Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)